Fundraising FoxPivotal Life Sciences — 2025 Investments
3 investments dated 2025 · listed companies and verified rows first · show all
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)in
BoardSerge Messerlian(Director)inCariad Chester(Director)in
Board seatRob Hopfner· per SEC Form D
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesSoftBank Vision Fund+3 more
Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.
BiotechHealthtechSouth San Francisco, US
Kathleen Collins(Director)inLawrence Kong(Executive Officer)inRon Park(President & CEO)inFrancine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in
BoardJayson Punwani(Director)in
Co-investorsBEVCSR One Capital ManagementAbingworth
Mosanna is a pharmaceutical company developing a non-invasive nasal spray therapy for obstructive sleep apnea (OSA) that reactivates the body's natural airway reflex to keep the upper airway open during sleep.
BiotechDigital HealthHealthtechMedical Devices
Barbara(Regulatory Affairs & Quality Assurance leadership)Kevin(Pharmaceutical Development leadership)Pranav(Head of Finance & Operations)Ben(Executive / Board)
BoardDavid White(Sleep Medicine Advisor)
Co-investorsBroadview VenturesNorwest Venture PartnersSupermoon CapitalForbionHTGFInkef
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.